Image

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 559.33 USD Million
Diagram Market Size (Forecast Year) USD 891.50 USD Million
Diagram CAGR %

Major Markets Players

  • Pfizer
  • F. Hoffmann La Roche Ltd
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market, By Type (Acute ITP, Chronic ITP, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Market Analysis and Size

The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is expected to witness significant growth during the forecast period. Growing cases of blood immune disorders drives the idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of idiopathic thrombocytopenic purpura (Immune Thrombocytopenic Purpura) treatment drugs market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market in the forecast period 2022-2029. The expected CAGR of global idiopathic thrombocytopenic purpura (Immune Thrombocytopenic Purpura) treatment drugs market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 559.33 million in 2021, and it would grow upto USD 891.5 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Idiopathic thrombocytopenic purpura is the type of immune disorder in which blood does not clot normally. It is also known as immune thrombocytopenic purpura. Platelets which are produced in the bone marrow helps in the clotting function and prevent us from the excessive bleeding. It can cause excessive bruising and bleeding and form purple bruises on the skin or mucous membrane inside the mouth. Symptoms include bruising, prolonged bleeding from cuts & wounds, blood in the stools & urine and others.  

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Acute ITP, Chronic ITP, Others), Treatment (Medication, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland)

Market Opportunities

  • Increased Potential Commercialization
  • Increasing Demand for Retail Pharmacies

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Dynamics

Drivers

  • Prevalence of Idiopathic Thrombocytopenic Purpura

The occurrence of cases of idiopathic thrombocytopenic purpura boosts the growth of the market. As per the European Medicines Agency (EMEA) records, the incidence rate of ITP rise high to 1.6 to 3.9 cases per 100,000 per year in Europe. This boosts the market growth.

  • Growing Demand For Combination Therapies

The rising demand for combination therapies is expected to boost the market growth of the idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs. Studies showed that combination therapies have relatively lower side effects, and are cost-effective, and show higher response rates in patients. Some major combination therapies include rituximab and dexamethasone, corticosteroids and IVIG, TPO-RA (eltrombopag), and dexamethasone.

Opportunities

  • Increased Potential Commercialization

The potential commercialization of new products such as avatrombopag by Eisai and IVIG3I 10% by Grifols, is surely boosting the market growth. Avatrombopag has showed positive clinical trial results and is expected to benefit patients with a second line of treatment upon commercialization. This creates more opportunity for the market growth.

  • Increasing Demand for Retail Pharmacies

Rise in the number of drugs for idiopathic thrombocytopenic purpura being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Side Effects of Treatments

There are various side-effects associated with the treatment options of idiopathic thrombocytopenic purpura. Treatments such as Splenectomy have side effects such as bleeding, blood clots, bleeding, infection. Excessive use of corticosteroids can also lead to side effects such as vomiting, nausea and many others. Thus, this hampers the market growth.

  • High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Scope

The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Acute ITP
  • Chronic ITP
  • Others

Treatment

  • Medication
  • Surgery
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Regional Analysis/Insights

The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market throughout the forecasted period due to enhanced prevalence of iron deficiency anaemia and related disorders and number of generic drugs.

North America dominates the market due to increased presence of key manufacture of the product.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment Drugs Market Share Analysis

The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market.

Key players operating in the global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market include:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Novartis AG (Switzerland)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The global idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) treatment drugs market is expected USD 891.5 million by 2029.
The major players operating in the Idiopathic Thrombocytopenic Purpura Treatment Drugs Market are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland).
The Idiopathic Thrombocytopenic Purpura Treatment Drugs Market is to grow at a CAGR of 6% during the forecast by 2029.
The major countries covered in the Idiopathic Thrombocytopenic Purpura Treatment Drugs Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials